Back to top
more

Cytokinetics (CYTK)

(Delayed Data from NSDQ)

$62.10 USD

62.10
1,343,709

-1.92 (-3.00%)

Updated May 10, 2024 04:00 PM ET

After-Market: $62.00 -0.10 (-0.16%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (84 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for CYTK

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Cytokinetics, Incorporated [CYTK]

Reports for Purchase

Showing records 261 - 280 ( 305 total )

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 261

04/19/2012

Daily Note

Pages: 8

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 25.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 262

03/07/2012

Daily Note

Pages: 18

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 50.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 263

03/07/2012

Company Report

Pages: 4

A Busy Week

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 264

03/07/2012

Daily Note

Pages: 3

A Busy Week

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 265

03/06/2012

Company Report

Pages: 4

''357 Receives EMA Orphan Status; Data Points in April

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 266

02/22/2012

Company Report

Pages: 4

Initiation of Phase I Trial of Oral Omecamtiv Indicative of AMGN''s Continued Interest

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 267

02/22/2012

Daily Note

Pages: 3

Initiation of Phase I Trial of Oral Omecamtiv Indicative of AMGN''s Continued Interest

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 268

02/03/2012

Daily Note

Pages: 3

4Q11 and YE2011 Earnings: A Recap of Clinical Progress and Outlook for 2012

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 269

02/03/2012

Company Report

Pages: 6

4Q11 and YE2011 Earnings: A Recap of Clinical Progress and Outlook for 2012

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 25.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 270

02/01/2012

Daily Note

Pages: 3

4Q11 Earnings Call Preview

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 271

02/01/2012

Daily Note

Pages: 4

4Q11 Earnings Call Preview

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 272

12/08/2011

Daily Note

Pages: 3

Transfer of Coverage: Maintaining a Market Outperform Rating

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 273

12/08/2011

Company Report

Pages: 7

Transfer of Coverage: Maintaining a Market Outperform Rating

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 25.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 274

12/07/2011

Daily Note

Pages: 3

We are under review due to the departure from the firm of analyst

Provider: RODMAN & RENSHAW, CO.

Price: 10.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 275

12/07/2011

Daily Note

Pages: 3

We are under review due to the departure from the firm of analyst

Provider: RODMAN & RENSHAW, CO.

Price: 10.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 276

12/02/2011

Daily Note

Pages: 3

Two Weeks of Dosing of Skeletal Muscle Activator in ALS Patients Supports Safety Profile

Provider: RODMAN & RENSHAW, CO.

Analyst: NOCHOMOVITZ Y

Price: 10.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 277

12/02/2011

Daily Note

Pages: 5

Two Weeks of Dosing of Skeletal Muscle Activator in ALS Patients Supports Safety Profile

Provider: RODMAN & RENSHAW, CO.

Analyst: NOCHOMOVITZ Y

Price: 10.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 278

11/02/2011

Daily Note

Pages: 10

MORNING SUMMARY

Provider: RODMAN & RENSHAW, CO.

Price: 25.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 279

11/01/2011

Company Report

Pages: 5

Skeletal Muscle Activator Program in ALS Moves Forward With Riluzole Combination Cohort

Provider: RODMAN & RENSHAW, CO.

Analyst: NOCHOMOVITZ Y

Price: 10.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 280

11/01/2011

Daily Note

Pages: 3

Skeletal Muscle Activator Program in ALS Moves Forward With Riluzole Combination Cohort

Provider: RODMAN & RENSHAW, CO.

Analyst: NOCHOMOVITZ Y

Price: 10.00

Research Provided by a Third Party